When someone is diagnosed with chronic leukaemia, the first focus is often the cancer itself. What stage is it? How active is it? What are the treatment options?But in real life, very few patients ...

After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.

Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc.

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...

Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...

In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.

Phase III results put obinutuzumab in line for approval ...

Health care costs in America can change as quickly as a diagnosis. One month, a treatment is manageable; the next, a coverage shift or a single high bill can make that same care feel out of reach.

The chief constable of Warwickshire Police plans to run this year's London Marathon in support of a cancer charity that has ...

The FDA has approved the first all-oral, fixed-duration first-line regimen for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.Acalabrutinib (Calquence, AstraZeneca) tablets ...